

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT
OWEN ET AL.
FILING DATE

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>mt</i>	AM	00/16804	3/30/00	WO	—	—	<input type="checkbox"/>	<input type="checkbox"/>
<i>mt</i>	AN	01/90110	11/29/01	WO	—	—	<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

<i>mt</i>	AR	Busse et al., "Omalizumab, Anti-IgE Recombinant Humanized Monoclonal Antibody, for the Treatment of Severe Allergic Asthma", Journal of Allergy and Clinical Immunology, Vol. 108, No. 2, pp. 184-190 (2001).
<i>mt</i>	AS	Heusser et al., "Therapeutic Potential of Anti-IgE Antibodies", Current Opinion in Immunology, Vol. 9, No. 6, pp. 805-813 (1997).
<i>mt</i>	AT	Kuehr et al., "Omalizumab (Xolair(R) RHUMAB-E25) in Children with Seasonal Allergic Rhinitis to Birch and Grass Pollen: Superior Efficacy of Xolair Plus Specific Immunotherapy over Specific Immunotherapy Alone During Grass Pollen Season", Allergy, Vol. 56, No. Suppl. 68, pp. 93-94 (2001).

EXAMINER

DATE CONSIDERED

12/16/05

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.